SCHEMBL20913985

SCHEMBL20913985

Cc1[nH]c2c(-c3ccccc3)cnn2c(=O)c1-c1cnoc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLAT P00750 3/20 0.39
▸ PTGS2 P35354 6/20 0.38
▸ NPC1 O15118 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CASP3 P42574 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SENP8 Q96LD8 1/20 0.35
▸ SENP7 Q9BQF6 1/20 0.35
▸ SENP6 Q9GZR1 1/20 0.35
▸ PTGS1 P23219 1/20 0.35
▸ PDGFRA P16234 1/20 0.35
▸ MAPK8 P45983 1/20 0.35
▸ CDK5 Q00535 1/20 0.35
▸ CLK4 Q9HAZ1 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914416 0.77 BRD4 (0.39) PLATPTGS2NPC1MEN1CASP3
SCHEMBL20931303 0.77 CDK5 (0.35) MEN1KMT2APDGFRAMAPK8CDK5
SCHEMBL16792069 0.71 ALKBH3 (0.43) PLATNPC1MEN1KMT2AGAA
SCHEMBL16092479 0.71 MDM2 (0.52) PLATMEN1KMT2APDGFRAMAPK8
SCHEMBL20913970 0.71 HSD17B10 (0.47) PLATNPC1CASP3SENP8SENP7
SCHEMBL16535047 0.68 AURKA (0.46) PLATNPC1MEN1KMT2AALOX15
SCHEMBL13516070 0.66 ALKBH3 (0.48) PTGS2NPC1KMT2APTGS1MAPT
SCHEMBL4048020 0.65 HPGD (0.52) PLATRAB9A
SCHEMBL16534969 0.63 GRM4 (0.46) SMN1; SMN2
SCHEMBL20914241 0.62 MEN1 (0.42) MEN1KMT2APDGFRAMAPK8CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 PLAT 1323/4885PTGS2 601/4885NPC1 2215/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 PLAT 1323/4885PTGS2 601/4885NPC1 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback